John T. McDevitt now serves as a Full Professor within the Department of Biomaterials at New York University, is a member of NYU’s Bioengineering Institute and participates as a faculty member in the NYU Department of Chemical and Biomolecular Engineering within the Tandon School of Engineering. Prior to this time, he served for 5 years as the Brown-Weiss Professor of Bioengineering and Chemistry at Rice University and rose through the academic ranks at University of Texas at Austin where he was positioned for 20 years. McDevitt completed his Ph.D. degree in Chemistry from Stanford University.

Professor McDevitt is a pioneer in the development of ‘programmable bio-nano-chip’ technologies. He has a strong track record of translating essential bioscience, artificial intelligence and medical microdevice discoveries into real-world clinical practice. In this capacity, he has served as the Scientific Founder for a number of diagnostic and clinical services companies including OraLiva which features smart diagnostics for early disease detection as well as SensoDx which develops and monetizes programmable diagnostic hardware. McDevitt and his team have raised over $45M in Federal and Foundation support. His recent research has been sponsored by major programs funded by National Institute of Dental and Craniofacial Research (NIDCR) division of the National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA) at NIH,  Bill and Melinda Gates Foundation, Cancer Prevention Research Institute of Texas (CPRIT), NASA (National Aeronautics and Space Administration), Renaissance Health Service Corporation (Delta Dental of MI), the Army and the United Kingdom’s Home Office Scientific Development Branch.

McDevitt and his team have written more than 200 peer-reviewed scientific manuscripts and have contributed to more than 100 patents and patent applications. This work was recognized with the “2020 People’s Choice Award for the TOPx COVID-19 initiative”, “2016 AACC Wallace H. Coulter Lectureship Award,” “Best of What’s New Award” in the Medical Device Category by Popular Science as well as for the “Best Scientific Advances Award” by the Science Coalition. Dr. McDevitt’s individual honors include the Presidential Young Investigator Award, the California Polytechnic Distinguished Alumni Award and the Exxon Education Award. Over the past years, Dr. McDevitt has served as the Principal Investigator for 6 major clinical trials and 2 clinical pilot studies, all involving the programmable bio-nano-chip. Through these clinical efforts, mini-sensor ensembles are being developed for major diseases in the areas of COVID-19 disease severity, oral cancer, cardiac heart disease, trauma, drugs of abuse, ovarian cancer and prostate cancer.

IMPORTANT DATES
May
21
2021

Final Extended Paper Submission Deadlines

May
28
2021

Final Extended Notification to Authors

Jun
8
2021

Final Extended Early-Bird Registration